13th Process Development for Highly Potent Drugs Summit (HPAPI)

From Process Safety to Rapid Scale-Up to Tech Transfer: Integrating Process Development, Industrial Hygiene and Equipment Selection to Achieve GMP Manufacturing of Novel High Potent Drug Compounds 2023 has been a pivotal year for novel high potent compounds securing early success and approvals – from Henlius’s ADC to Gilead’s Trodelvy to BMS’s Augtyro, cementing the growth of highly potent drugs market to reach USD$40.7bn by 2023.

The rise in novel, more potent compounds, alongside EU Annex 1, are mounting pressure on biopharma, CDMOs and equipment providers to evolve their industrial hygiene, process engineering and manufacturing capabilities to ensure safe handling and effective scale-up to achieve commercial GMP manufacturing. The 13th HPAPI: Process Development for Highly Potent Drugs Summit is your definitive community to evaluate efficient high potent compounds synthesis, adoption of innovative technology platforms and occupational safety best practice.

Time: 1:30 PM – 3:45 PM

Venue details: Delta Hotel Philadelphia Airport, 500 Stevens Drive, Philadelphia, Pennsylvania, 19113, United States

Prices: USD 2599.00 – USD 5197.00

Speakers: Antonio Hernandez-Cardoso, Senior Principal Scientist, US Pharmacopiea, David Cragin, Senior Director – Product Science, Environment, Health, Safety and Sustainability, Teva Pharmaceuticals, and more